SURGERY PARTNERS INC (SGRY) Stock Fundamental Analysis
NASDAQ:SGRY - Nasdaq - US86881A1007 - Common Stock - Currency: USD
Overall SGRY gets a fundamental rating of 3 out of 10. We evaluated SGRY against 109 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of SGRY while its profitability can be described as average. SGRY has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year SGRY was profitable.
In the past year SGRY had a positive cash flow from operations.
In the past 5 years SGRY always reported negative net income.
SGRY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
SGRY's Return On Assets of -0.80% is in line compared to the rest of the industry. SGRY outperforms 51.85% of its industry peers.
SGRY has a Return On Equity (-3.20%) which is in line with its industry peers.
With a decent Return On Invested Capital value of 5.07%, SGRY is doing good in the industry, outperforming 61.11% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for SGRY is below the industry average of 8.07%.
The 3 year average ROIC (4.74%) for SGRY is below the current ROIC(5.07%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.8% | ||
| ROE | -3.2% | ||
| ROIC | 5.07% |
ROA(3y)-0.77%
ROA(5y)-1.48%
ROE(3y)-3.6%
ROE(5y)-11.01%
ROIC(3y)4.74%
ROIC(5y)4.35%
1.3 Margins
SGRY's Operating Margin of 14.98% is amongst the best of the industry. SGRY outperforms 91.67% of its industry peers.
In the last couple of years the Operating Margin of SGRY has remained more or less at the same level.
With a Gross Margin value of 26.59%, SGRY perfoms like the industry average, outperforming 52.78% of the companies in the same industry.
In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.98% | ||
| PM (TTM) | N/A | ||
| GM | 26.59% |
OM growth 3Y14.22%
OM growth 5Y1.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.06%
GM growth 5Y-0.98%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SGRY is destroying value.
Compared to 1 year ago, SGRY has more shares outstanding
SGRY has more shares outstanding than it did 5 years ago.
SGRY has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.90, we must say that SGRY is in the distress zone and has some risk of bankruptcy.
SGRY's Altman-Z score of 0.90 is on the low side compared to the rest of the industry. SGRY is outperformed by 66.67% of its industry peers.
SGRY has a debt to FCF ratio of 19.53. This is a negative value and a sign of low solvency as SGRY would need 19.53 years to pay back of all of its debts.
SGRY has a Debt to FCF ratio (19.53) which is in line with its industry peers.
SGRY has a Debt/Equity ratio of 1.63. This is a high value indicating a heavy dependency on external financing.
SGRY has a Debt to Equity ratio of 1.63. This is in the lower half of the industry: SGRY underperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.63 | ||
| Debt/FCF | 19.53 | ||
| Altman-Z | 0.9 |
ROIC/WACC0.65
WACC7.8%
2.3 Liquidity
A Current Ratio of 1.80 indicates that SGRY should not have too much problems paying its short term obligations.
SGRY has a better Current ratio (1.80) than 67.59% of its industry peers.
SGRY has a Quick Ratio of 1.66. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.66, SGRY is in the better half of the industry, outperforming 62.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.66 |
3. Growth
3.1 Past
SGRY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.63%, which is quite good.
Looking at the last year, SGRY shows a quite strong growth in Revenue. The Revenue has grown by 9.96% in the last year.
SGRY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.14% yearly.
EPS 1Y (TTM)14.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)9.96%
Revenue growth 3Y13.83%
Revenue growth 5Y9.14%
Sales Q2Q%14.29%
3.2 Future
Based on estimates for the next years, SGRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.88% on average per year.
Based on estimates for the next years, SGRY will show a quite strong growth in Revenue. The Revenue will grow by 10.64% on average per year.
EPS Next Y-10.76%
EPS Next 2Y-0.54%
EPS Next 3Y7.63%
EPS Next 5Y15.88%
Revenue Next Year11.94%
Revenue Next 2Y10.94%
Revenue Next 3Y10.38%
Revenue Next 5Y10.64%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
SGRY is valuated quite expensively with a Price/Earnings ratio of 27.34.
Compared to the rest of the industry, the Price/Earnings ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 62.96% of the companies listed in the same industry.
SGRY is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.47, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 26.24 indicates a quite expensive valuation of SGRY.
SGRY's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 92.74, SGRY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.34 | ||
| Fwd PE | 26.24 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SGRY is valued a bit cheaper than the industry average as 75.93% of the companies are valued more expensively.
SGRY's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 75.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.99 | ||
| EV/EBITDA | 10.45 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.54%
EPS Next 3Y7.63%
5. Dividend
5.1 Amount
No dividends for SGRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SURGERY PARTNERS INC
NASDAQ:SGRY (2/4/2025, 8:07:27 PM)
After market: 25.7 0 (0%)25.7
+0.4 (+1.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners74.05%
Inst Owner Change0.14%
Ins Owners1.11%
Ins Owner Change0.25%
Market Cap3.27B
Analysts80
Price Target33.99 (32.26%)
Short Float %13.94%
Short Ratio7.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.52%
Min EPS beat(2)-26.04%
Max EPS beat(2)2.99%
EPS beat(4)3
Avg EPS beat(4)6.96%
Min EPS beat(4)-26.04%
Max EPS beat(4)37.02%
EPS beat(8)7
Avg EPS beat(8)279.34%
EPS beat(12)8
Avg EPS beat(12)143.98%
EPS beat(16)12
Avg EPS beat(16)146.7%
Revenue beat(2)1
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-1.88%
Max Revenue beat(2)1.58%
Revenue beat(4)2
Avg Revenue beat(4)-0.59%
Min Revenue beat(4)-2.77%
Max Revenue beat(4)1.58%
Revenue beat(8)3
Avg Revenue beat(8)-0.76%
Revenue beat(12)4
Avg Revenue beat(12)-1.17%
Revenue beat(16)6
Avg Revenue beat(16)-0.97%
PT rev (1m)-4.61%
PT rev (3m)-15.59%
EPS NQ rev (1m)-4.19%
EPS NQ rev (3m)-17.98%
EPS NY rev (1m)-2.98%
EPS NY rev (3m)-18.36%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-1.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.34 | ||
| Fwd PE | 26.24 | ||
| P/S | 1.09 | ||
| P/FCF | 19.99 | ||
| P/OCF | 13 | ||
| P/B | 1.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.45 |
EPS(TTM)0.94
EY3.66%
EPS(NY)0.98
Fwd EY3.81%
FCF(TTM)1.29
FCFY5%
OCF(TTM)1.98
OCFY7.69%
SpS23.49
BVpS14.92
TBVpS-23.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.8% | ||
| ROE | -3.2% | ||
| ROCE | 6.43% | ||
| ROIC | 5.07% | ||
| ROICexc | 5.24% | ||
| ROICexgc | 18.8% | ||
| OM | 14.98% | ||
| PM (TTM) | N/A | ||
| GM | 26.59% | ||
| FCFM | 5.47% |
ROA(3y)-0.77%
ROA(5y)-1.48%
ROE(3y)-3.6%
ROE(5y)-11.01%
ROIC(3y)4.74%
ROIC(5y)4.35%
ROICexc(3y)4.98%
ROICexc(5y)4.55%
ROICexgc(3y)18.31%
ROICexgc(5y)17.7%
ROCE(3y)6.01%
ROCE(5y)5.51%
ROICexcg growth 3Y8.18%
ROICexcg growth 5Y-7.94%
ROICexc growth 3Y17.44%
ROICexc growth 5Y2.3%
OM growth 3Y14.22%
OM growth 5Y1.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.06%
GM growth 5Y-0.98%
F-Score3
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.63 | ||
| Debt/FCF | 19.53 | ||
| Debt/EBITDA | 5.18 | ||
| Cap/Depr | 58.68% | ||
| Cap/Sales | 2.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 42.09% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 0.9 |
F-Score3
WACC7.8%
ROIC/WACC0.65
Cap/Depr(3y)67.9%
Cap/Depr(5y)69.03%
Cap/Sales(3y)3%
Cap/Sales(5y)3.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-10.76%
EPS Next 2Y-0.54%
EPS Next 3Y7.63%
EPS Next 5Y15.88%
Revenue 1Y (TTM)9.96%
Revenue growth 3Y13.83%
Revenue growth 5Y9.14%
Sales Q2Q%14.29%
Revenue Next Year11.94%
Revenue Next 2Y10.94%
Revenue Next 3Y10.38%
Revenue Next 5Y10.64%
EBIT growth 1Y10.64%
EBIT growth 3Y30.01%
EBIT growth 5Y10.74%
EBIT Next Year26.45%
EBIT Next 3Y16.73%
EBIT Next 5YN/A
FCF growth 1Y64.55%
FCF growth 3Y0.16%
FCF growth 5Y14.36%
OCF growth 1Y46.7%
OCF growth 3Y5.97%
OCF growth 5Y15.23%